Limited Value of KAI1/CD82 Protein Expression as a Prognostic Marker in Human Gastric Cancer

Knoener, Maximilian; Krech, Till; Puls, Florian; Lehmann, Ulrich; Kreipe, Hans; Christgen, Matthias

doi:10.1155/2012/737132

Cited by 10 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with earlier data on KAI1 expression in gastric, breast, head and neck cancers [14,20,21], we observed a loss of KAI1 protein expression in almost half of primary endometrial cancers. KAI1--negative tumors were found frequently in poorly differentiated cases, similarly to the situation previously described with gastric cancer [20].…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer

Gryboś

Bär

2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The role of the parallel expression of the KAI1 protein and metalloproteinases (MMP-2 and MMP-9) in respect to the status of steroid receptors in endometrial cancer is still incompletely understood. The aim of this study was to evaluate the expression of and correlation between KAI1 on one hand and MMP-2 and MMP-9 on the other hand in terms of the status of the estrogen (ER) and progesterone receptors (PR) in 100 patients with endometrial cancer. The expressions of KAI1, MMP-2, MMP-9, ER and PR were assessed immunohistochemically on paraffin-embedded tissues. No correlations were found between these biomarkers and the clinical and pathological parameters of the endometrial cancer. However, in KAI1-positive cases, the expression was limited to a small area of tumor tissue in FIGO stages III-IV. A tendency towards the high expression of MMP-9 and MMP-2 was observed in the advanced stages of endometrial cancer (FIGO IIIA-IV). Positive correlations between the presence of KAI1 and PR and between the presence of MMP-9 and PR were found in endometrial cancer. A positive correlation was also observed between KAI1 and MMP-2 expression, and a borderline one between KAI1 and MMP-9 expression in endometrial cancer. KAI1 -/MMP-2 + and KAI1 -/MMP-9 + phenotypes were more often observed in FIGO stage II. Our study showed that KAI1 protein, as well as steroid receptors, might modulate MMP-2 and MMP-9 expression in endometrial cancer. Our study revealed that the overlapping expression of the biomarkers investigated here suggests that cooperation between these molecules exists, even at the early stages of endometrial cancer growth, and may determine the speed of tumor cell dissemination and might characterize the biological behavior of endometrial cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

“…KAI1--negative tumors were found frequently in poorly differentiated cases, similarly to the situation previously described with gastric cancer [20]. In our study, KAI1 downregulation was not significantly associated with an advanced clinical stage of disease.…”

Section: Discussionsupporting

confidence: 90%

The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer

Gryboś

Bär

2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…Loss of KAI1 expression was likely to predict metastasis and poor clinical outcome in gastric cancer patients. For the purpose of predicting the prognosis of gastric cancer patients, it was important to discriminate whether the carcinoma cells have loss of KAI1 expression 18. VEGF was the most well-characterized angiogenic factor closely associated with tumor progression and prognosis in several carcinogenesis 19.…”

Section: Discussionmentioning

confidence: 99%

Expression Characteristics of KAI1 and Vascular Endothelial Growth Factor and Their Diagnostic Value for Hepatocellular Carcinoma

Zhao

Sun

et al. 2014

Gut Liver

View full text Add to dashboard Cite

Background/AimsWe tried to investigate the expression characteristics of KAI1, a suppressor of wide-spectrum tumor metastasis, and vascular endothelial growth factor (VEGF), the most common angiogenesis factor, and then to analyze their diagnostic value for hepatocellular carcinoma (HCC).MethodsThe protein and mRNA expression levels of KAI1 or VEGF in HCC tissues and in self-controlled para-carcinoma tissues were analyzed by Western blot and real-time polymerase chain reaction, respectively. Serum levels of KAI1 and VEGF in the patients with HCC, benign liver disease or in healthy controls were quantitatively detected by enzyme-linked immunosorbent assay.ResultsThe expression level of KAI1 was downregulated, while the expression level of VEGF was upregulated in the tissues or serum of the patients with HCC. The expression level of serum KAI1 in HCC patients was correlated with TNM staging, intrahepatic metastasis, lymph node or peritoneal metastasis, and portal vein thrombus. In addition to the factors that were correlated with KAI1 expression, VEGF expression was also closely related to the α-fetoprotein level of the patients. The area under the receiver operating characteristic curve for the diagnosis of HCC was 0.907 for KAI1 and 0.779 for VEGF. The sensitivity of serum KAI1 levels in the diagnosis of HCC was 86.96%; the accuracy was 83.06%, while the sensitivity, the accuracy and the negative predictive value were improved to 91.86%, 84.68%, and 78.79% according to the combined detection of KAI1 and VEGF, respectively.ConclusionsA combined detection of KAI1 and VEGF may greatly improve the efficiency of diagnosis and form a reliable panel of diagnostic markers for HCC.

show abstract

“…[38][39][40][41][42] These findings suggest that high expression of CD82 and BCL2L12 in colon and gastric cancer may correlate with favorable prognosis, but in hematologic malignancies may be associated with poor outcome, indicating cancer type-specific biological functions of these molecules. Therefore, the manipulation of CD82 and BCL2L12 expression may constitute a therapeutic approach to AML treatment.…”

Section: Immunodeficient Mice Transplanted With Bcl2l12-depleted Molmmentioning

confidence: 99%

The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells

et al. 2015

View full text Add to dashboard Cite

The aim of this study was to explore the biological functions of a tetraspanin family protein CD82 expressed aberrantly in chemotherapy-resistant CD34(+)/CD38(-) acute myelogenous leukemia (AML) cells. Microarray analysis of patient-isolated CD34(+)/CD38(-) AML cells revealed that the levels of anti-apoptotic protein BCL2L12 were downregulated after CD82 depletion by specific short hairpin RNA (shRNA). Western blot analysis indicated that BCL2L12 was aberrantly expressed in patient-isolated AML cells and AML cell lines. Furthermore, CD82 blockade by a specific antibody downregulated BCL2L12 in parallel with dephosphorylation of signal transducer and activator of transcription 5 (STAT5) and AKT, whereas pharmacological inhibition of STAT5 and AKT activation decreased BCL2L12 expression in leukemia cells. In addition, shRNA-mediated downregulation of BCL2L12 increased the levels of cleaved caspase-3 and suppressed proliferation of leukemia cells, impairing their engraftment in immunodeficient mice. Taken together, our results indicate that CD82 regulated BCL2L12 expression via STAT5A and AKT signaling and stimulated proliferation and engrafting of leukemia cells, suggesting that CD82 and BCL2L12 may be promising therapeutic targets in AML.

show abstract

Limited Value of KAI1/CD82 Protein Expression as a Prognostic Marker in Human Gastric Cancer

Cited by 10 publications

References 15 publications

The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer

The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer

Expression Characteristics of KAI1 and Vascular Endothelial Growth Factor and Their Diagnostic Value for Hepatocellular Carcinoma

The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells

Contact Info

Product

Resources

About